Advertisement

Advertisement
Solid Tumors
Issues in Oncology

Long-Term Low-Grade Intestinal Inflammation May Be Prevalent Among Patients Who Have Undergone Radiotherapy

Researchers have found that low-grade intestinal inflammation may be a side effect of radiotherapy, according to a recent study published by...

Breast Cancer
Lung Cancer
Skin Cancer
Gastrointestinal Cancer
Immunotherapy

Neoadjuvant Immune Checkpoint Blockade May Be Effective Across Multiple Cancer Types

Neoadjuvant immunotherapy may be effective prior to surgery in multiple types of cancers, according to a recent study published by...

Hepatobiliary Cancer

Tucatinib/Trastuzumab for Previously Treated Patients With HER2-Positive Metastatic Biliary Tract Cancer

As reported in the Journal of Clinical Oncology by Nakamura et al, findings in a cohort of the phase II SGNTUC-019 basket study showed that tucatinib...


Advertisement
Genomics/Genetics

FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types

On September 29, the U.S. Food and Drug Administration (FDA) granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro...

Solid Tumors
Issues in Oncology

Prophylactic Radiation for High-Risk Asymptomatic Bone Metastases

In a phase II trial reported in the Journal of Clinical OncologyErin F. Gillespie, MD, MPH, and colleagues found that prophylactic radiotherapy in patients...

Advertisement




Breast Cancer

Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment

Skin Cancer
Immunotherapy

Extended Follow-up of Nivolumab/Ipilimumab for Metastatic Melanoma

In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive at a median of 6.5 years after treatment. These long-term results from the...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Multiple Myeloma

Taiga Nishihori, MD, on Multiple Myeloma: Maintenance Ixazomib After Transplant

Breast Cancer

Adjuvant Platinum vs Capecitabine in Patients With Basal Subtype Triple-Negative Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy

As reported in the Journal of Clinical Oncology and during the 2021 ASCO Annual Meeting by Ingrid A. Mayer, MD, and colleagues, the phase III ECOG-ACRIN EA1131 trial investigated the use of adjuvant platinum vs capecitabine in patients with basal subtype triple-negative breast cancer and residual...

Kidney Cancer
Immunotherapy

No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes

A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer
Immunotherapy

Nadia Harbeck, MD, PhD, on Early Breast Cancer: Benefit of a De-escalated Regimen

Lung Cancer
Genomics/Genetics

Global Registry Analysis of NRG1 Fusion–Positive Lung Cancer

In an analysis from the global eNRGy1 registry for NRG1 fusion–positive lung cancers reported in the Journal of Clinical Oncology, Alexander Drilon, MD, and colleagues found greater than expected heterogeneity in characteristics of disease. Additionally, patients had poor responses to cytotoxic,...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter